Fig. 3: Treatment of SAR131675 decreases LYVE-1 (+) lymphatic vessel expression in the resiquimod-induced lupus nephritis. | Cell Death Discovery

Fig. 3: Treatment of SAR131675 decreases LYVE-1 (+) lymphatic vessel expression in the resiquimod-induced lupus nephritis.

From: Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model

Fig. 3

A Representative sections of kidneys from each experimental group of SAR131675 treatment in the resiquimod-induced LN were immunofluorescence stained with LYVE-1 and VEGFR-3; Scale bar=50 μm. B Quantitative RT-PCR analyses for Lyve-1, Pdpn, Prox-1, and Vegfr-3 mRNA expression were performed using mRNA from each experimental group of SAR131675 treatment in the resiquimod-induced LN. Expression levels are normalized to Gapdh. C Representative Western blot analysis of VEGFR-3 protein expression from each experimental group of SAR131675 treatment in the resiquimod-induced LN. The graph shows the densitometric quantification of Western blot bands by ImageJ software. Expression levels are normalized to HSP90. Statistical significance was determined using one-way ANOVA followed by Tukey’s post-hoc test. Data are expressed as mean ± SD. ***P < 0.001, ****P < 0.0001 versus each group. Control, vehicle-treated group; SAR, SAR131675-treated group; Lupus, resiquimod-treated group; Lupus+SAR, resiquimod and concomitantly SAR131675-treated group. DAPI 4’,6-diamidino-2-phenylindole, LN lupus nephritis, LYVE-1 lymphatic vessel endothelial hyaluronan receptor-1, Pdpn podoplanin, Prox-1 prospero-related homeobox 1, VEGFR-3 vascular endothelial growth factor receptor-3.

Back to article page